Program
Polymyxin B
Also written as “Polymyxin B (50 mg)” and “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”.
Its studies are mostly in Pneumonia, Bacterial · Eczema, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioVersys SAS | 22 open or running | phase 3since Jan 7, 2026 | Jan 7, 2026 | Dec 30, 2027phase 3 · NCT07326540 |
| EMS | 10 open or running | phase 3since Sep 5, 2011 | Sep 5, 2011 | none ahead |
| TTY Biopharm | 10 open or running | phase 1since Mar 29, 2022 | Mar 29, 2022 | none ahead |
Also a collaborator on its studies: bioversys-ag.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2011First study: phase 3 study in EczemaNew to EMSEMS · NCT01429701 · 76 enrolled
- Mar 29, 2022TTY Biopharm's first study: phase 1 study in Antibiotic ToxicityNew to TTY BiopharmTTY Biopharm · NCT05359627 · 22 enrolled · Taiwan
- Jan 7, 2026BioVersys SAS's first study: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)New to BioVersys SASBioVersys SAS · NCT07326540 · 248 planned · Georgia
- Apr 28, 2026Phase 1 study in Healthy Adult ParticipantsBioVersys SAS · NCT07580586 · 16 planned · Austria
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)BioVersys SAS · NCT07326540
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cell outer membrane inhibitor”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07580586Healthy Adult Participants · Austria | 1 | Recruiting | BioVersys SAS | Sep 30, 2026 | 16 |
| NCT07326540Hospital Acquired Bacterial Pneumonia (HABP) · Georgia | 3 | Recruiting | BioVersys SAS | Dec 30, 2027 | 248 |
| NCT05359627Antibiotic Toxicity · Taiwan | 1 | Completed | TTY Biopharm | Mar 3, 2023 | 22 |
| NCT01429701Eczema | 3 | Completed | EMS | Jun 2012 | 76 |
How it is read
Names in the registry
- “Polymyxin B”, 2 entries
- “Polymyxin B (50 mg)”, 1 entry
- “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”, 1 entry
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 1 study
- Eczema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.